Daewoong takes over Turn Bio’s longevity platform from Hanall

May 26, 2026

Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd.

Daewoong takes over Turn Bio’s longevity platform from Hanall

May 22, 2026

By Marian (YoonJee) Chu

No Comments

Today's news in brief

BioWorld

BioWorld briefs for May 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 26, 2026

Microscopy of a cross-section of mouse skin containing melanoma tumors

Researchers identify innate immune barrier against melanoma

BioWorld

Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...

TROP2 ADCs progress into first-line for lung, breast cancers

BioWorld

Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...

Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

BioWorld Science

Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...